Studies of Org 10172 in patients with acute ischemic stroke. TOAST Study Group.
This report presents data from pilot studies of Org 10172 in the management of patients with acute ischemic stroke. The studies have established a potentially optimal dosage and treatment regimen and have provided information for the development of a large randomized trial. The trial of Org 10172 in acute stroke treatment is now underway in the United States.
Adams
H P
HP
Department of Neurology, University of Iowa College of Medicine, Iowa City 52242.
Woolson
R F
RF
Biller
J
J
Clarke
W
W
D002545:Brain Ischemia / Q000188:drug therapy* / Q000453:epidemiology; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004341:Drug Evaluation; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006025:Glycosaminoglycans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006496:Heparinoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006497:Heparan Sulfate; D006801:Humans; D015994:Incidence; D010865:Pilot Projects; D011516:Prothrombin / Q000037:antagonists & inhibitors; D015912:Thrombolytic Therapy; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006025:Glycosaminoglycans; D006496:Heparinoids; D006497:Heparan Sulfate; D011516:Prothrombin; C025337:Factor IIa; C035838:danaparoid